GGrantIndex
← Leaderboards

Brian J Druker

Oregon Health And Science University

Google Scholar ↗PubMed ↗ORCID ↗
$26,160,883
Attributed
$36,845,163
Total exposure
27
Grants
21
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $8.1M · FY2005–25
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$84,856,273 · 29

By mechanism

P30$44,244,484 · 16
U01$16,676,519 · 3
U54$13,135,684 · 3
R01$5,970,465 · 2
R25$2,075,391 · 1
R37$1,508,022 · 1

Top collaborators

Most similar at Oregon Health And Science University

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasms”

Research focus

Malignant NeoplasmsInstitutesProgramsResearch PersonnelResource SharingFundingCancer Center Support GrantMemberClinical TrialsLeadershipAnticancer ResearchInstructionMolecularClinical ResearchEnsureOregonResourcesEvaluationUniversitiesInnovationPharmaceutical PreparationsMeetingsTumorPathway Interactions

Grant awards (200)

Architecture and Trajectory of Acquired Resistance to Therapy in AML$1,308,996
U54 · FY2025 · CA
Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia$1,168,038
U01 · FY2025 · CA
Translating Improved Pairing and Timing of Drug Combination Strategies$304,150
U54 · FY2025 · CA · contact PI
Contribution of Inflammation to the Pathogenesis of RUNX1-FPDMM$37,500
U54 · FY2025 · CA
Architecture and Trajectory of Acquired Resistance to Therapy in AML$1,243,548
U54 · FY2024 · CA
Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia$1,109,637
U01 · FY2024 · CA
Translating Improved Pairing and Timing of Drug Combination Strategies$291,059
U54 · FY2024 · CA · contact PI
Leadership, Planning and Evaluation$69,269
P30 · FY2024 · CA · contact PI
Architecture and Trajectory of Acquired Resistance to Therapy in AML$1,308,998
U54 · FY2023 · CA
Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia$1,144,679
U01 · FY2023 · CA
Knight Scholars Program - Building STEM Interest and Capacity for Cancer Research Careers among Underrepresented and Rural High School Students$323,243
R25 · FY2023 · CA
Translating Improved Pairing and Timing of Drug Combination Strategies$304,147
U54 · FY2023 · CA · contact PI
OHSU Knight Federated Learning Network Prototype to Support Multimodal Cancer Models$299,750
P30 · FY2023 · CA · contact PI
OHSU Knight Cancer Institute$191,618
P30 · FY2023 · CA · contact PI
Leadership, Planning and Evaluation$69,269
P30 · FY2023 · CA · contact PI
OHSU Knight Cancer Institute$2,891,535
P30 · FY2022 · CA · contact PI
Architecture and Trajectory of Acquired Resistance to Therapy in AML$1,308,998
U54 · FY2022 · CA
Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia$1,181,536
U01 · FY2022 · CA
Knight Scholars Program - Building STEM Interest and Capacity for Cancer Research Careers among Underrepresented and Rural High School Students$485,730
R25 · FY2022 · CA
Translating Improved Pairing and Timing of Drug Combination Strategies$369,600
U54 · FY2022 · CA · contact PI
Understanding the origins of rapid recurrence of pancreatic cancer after resection$191,618
P30 · FY2022 · CA · contact PI
Administrative Supplement to Continue NCI-Supported Community Outreach Capacity through Community Health Educators of the National Outreach Network$115,000
P30 · FY2022 · CA · contact PI
Leadership, Planning and Evaluation$69,269
P30 · FY2022 · CA · contact PI
OHSU Knight Cancer Institute$2,310,000
P30 · FY2021 · CA · contact PI
Proteogenomic Translational Research Center for Clinical Proteomic$1,369,292
U01 · FY2021 · CA
Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AML$1,154,998
U54 · FY2021 · CA
Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies$1,004,844
U01 · FY2021 · CA · contact PI
Genetics and Signaling of Drug Resistance and Sensitivity in AML Cell Lines, Xenografts, and Primary Patient Samples$348,517
U54 · FY2021 · CA · contact PI
Characterizing the landscape of resistance and persistence mechanisms in CML$329,175
R01 · FY2021 · CA · contact PI
Knight Scholars Program - Building STEM Interest and Capacity for Cancer Research Careers among Underrepresented and Rural High School Students$299,571
R25 · FY2021 · CA
OHSU Knight Cancer Institute$249,999
P30 · FY2021 · CA · contact PI
ADMINISTRATIVE CORE AND SENIOR LEADERSHIP$209,977
P30 · FY2021 · CA · contact PI
HPV Vaccination EBI Adaptation in Collaboration with NPAIHB's NW Tribal Comprehensive Cancer and Knight Cancer Institute's Community Outreach & Engagement programs$150,000
P30 · FY2021 · CA · contact PI
OHSU Knight Cancer Institute$115,000
P30 · FY2021 · CA · contact PI
Dissecting Single-cell Response or resistance to novel combination therapy in AML using mass cytometry$93,333
U54 · FY2021 · CA
The National Cancer Institute (NCI) Cancer Clinical Investigator Team Leadership Award (CCITLA) P30 Administrative Supplement for Fiscal Year (FY) 2021$60,000
P30 · FY2021 · CA · contact PI
OHSU Knight Cancer Institute$2,310,000
P30 · FY2020 · CA · contact PI
Proteogenomic Translational Research Center for Clinical Proteomic$1,370,852
U01 · FY2020 · CA
Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AML$1,154,998
U54 · FY2020 · CA
Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies$1,004,844
U01 · FY2020 · CA · contact PI
OHSU Knight Cancer Institute$499,758
P30 · FY2020 · CA · contact PI
Genetics and Signaling of Drug Resistance and Sensitivity in AML Cell Lines, Xenografts, and Primary Patient Samples$348,518
U54 · FY2020 · CA · contact PI
Characterizing the landscape of resistance and persistence mechanisms in CML$329,175
R01 · FY2020 · CA · contact PI
OHSU Knight Cancer Institute$249,999
P30 · FY2020 · CA · contact PI
ADMINISTRATIVE CORE AND SENIOR LEADERSHIP$241,667
P30 · FY2020 · CA · contact PI
Understanding the impact on COVID-19 on health behaviors pertaining to cancer prevention, screening, and treatment activities and the mental health and well-being of cancer survivors$154,000
P30 · FY2020 · CA · contact PI
OHSU Knight Cancer Institute$150,000
P30 · FY2020 · CA · contact PI
OHSU Knight Cancer Institute$149,879
P30 · FY2020 · CA · contact PI
OHSU Knight Cancer Institute$115,000
P30 · FY2020 · CA · contact PI
OHSU Knight Cancer Institute$60,000
P30 · FY2020 · CA · contact PI
OHSU Knight Cancer Institute$2,310,000
P30 · FY2019 · CA · contact PI
Proteogenomic Translational Research Center for Clinical Proteomic$1,329,622
U01 · FY2019 · CA
Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AML$1,248,330
U54 · FY2019 · CA
Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies$1,236,369
U01 · FY2019 · CA · contact PI
Knight Scholars Program - Building STEM Interest and Capacity for Cancer Research Careers among Underrepresented and Rural High School Students$483,225
R25 · FY2019 · CA
ADMINISTRATIVE CORE AND SENIOR LEADERSHIP$351,143
P30 · FY2019 · CA · contact PI
Characterizing the landscape of resistance and persistence mechanisms in CML$319,299
R01 · FY2019 · CA · contact PI
OHSU Knight Cancer Institute$249,458
P30 · FY2019 · CA · contact PI
OHSU Knight Cancer Institute$199,624
P30 · FY2019 · CA · contact PI
OHSU Knight Cancer Institute$115,000
P30 · FY2019 · CA · contact PI
OHSU Knight Cancer Institute$60,000
P30 · FY2019 · CA · contact PI
OHSU Knight Cancer Institute$2,310,000
P30 · FY2018 · CA · contact PI
Proteogenomic Translational Research Center for Clinical Proteomic$1,372,508
U01 · FY2018 · CA
Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies$1,004,844
U01 · FY2018 · CA · contact PI
Knight Scholars Program - Building STEM Interest and Capacity for Cancer Research Careers among Underrepresented and Rural High School Students$483,622
R25 · FY2018 · CA
ADMINISTRATIVE CORE AND SENIOR LEADERSHIP$351,143
P30 · FY2018 · CA · contact PI
Characterizing the landscape of resistance and persistence mechanisms in CML$329,175
R01 · FY2018 · CA · contact PI
OHSU Knight Cancer Institute$248,465
P30 · FY2018 · CA · contact PI
OHSU Knight Cancer Institute$225,000
P30 · FY2018 · CA · contact PI
OHSU Knight Cancer Institute$124,966
P30 · FY2018 · CA · contact PI
ADMINISTRATIVE CORE AND SENIOR LEADERSHIP$16,566
P30 · FY2018 · CA · contact PI
ADMINISTRATIVE CORE AND SENIOR LEADERSHIP$15,001
P30 · FY2018 · CA · contact PI
ADMINISTRATIVE CORE AND SENIOR LEADERSHIP$8,332
P30 · FY2018 · CA · contact PI
OHSU Knight Cancer Institute$2,310,000
P30 · FY2017 · CA · contact PI
Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AML$2,309,994
U54 · FY2017 · CA
Proteogenomic Translational Research Center for Clinical Proteomic$1,374,609
U01 · FY2017 · CA
Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies$1,004,845
U01 · FY2017 · CA · contact PI
ADMINISTRATIVE CORE AND SENIOR LEADERSHIP$351,142
P30 · FY2017 · CA · contact PI
Characterizing the landscape of resistance and persistence mechanisms in CML$329,175
R01 · FY2017 · CA · contact PI
OHSU Knight Cancer Institute$174,792
P30 · FY2017 · CA · contact PI
OHSU Knight Cancer Institute$124,990
P30 · FY2017 · CA · contact PI
OHSU Knight Cancer Institute$1,479,340
P30 · FY2016 · CA · contact PI
OHSU Knight Cancer Institute$749,999
P30 · FY2016 · CA · contact PI
OHSU Knight Cancer Institute$124,995
P30 · FY2016 · CA · contact PI
OHSU Knight Cancer Institute$60,000
P30 · FY2016 · CA · contact PI
OHSU Knight Cancer Institute$1,540,000
P30 · FY2015 · CA · contact PI
Chronic Myelogenous Leukemia and BCR-ABL Substrates$310,293
R37 · FY2015 · CA · contact PI
Senior Leadership$228,272
P30 · FY2015 · CA · contact PI
Program Leadership$125,808
P30 · FY2015 · CA · contact PI
CLINICAL RESEARCH MANAGEMENT SHARED RESOURCE$125,798
P30 · FY2015 · CA · contact PI
DEVELOPMENTAL FUNDS$118,796
P30 · FY2015 · CA · contact PI
OHSU Knight Cancer Institute$93,744
P30 · FY2015 · CA · contact PI
DATA SAFETY MONITORING SYSTEMS$88,975
P30 · FY2015 · CA · contact PI
PROTOCOL REVIEW & MONITORING SYSTEM$79,629
P30 · FY2015 · CA · contact PI
PROGRAM PLANNING AND EVALUATION$77,674
P30 · FY2015 · CA · contact PI
PROTEOMICS SHARED RESOURCE$70,568
P30 · FY2015 · CA · contact PI
BIOANALYTICAL/PHARACOKINETIC SHARED RESOURCE$70,567
P30 · FY2015 · CA · contact PI
HISTAPATHOLOGY & CANCER GENOTYPING SHARED RESOURCE$67,814
P30 · FY2015 · CA · contact PI
FLOW CYTOMETRY SHARED RESOURCE$63,211
P30 · FY2015 · CA · contact PI
OHSU Knight Cancer Institute$60,000
P30 · FY2015 · CA · contact PI
PROTOCOL SPECIFIC RESEARCH SUPPORT$57,167
P30 · FY2015 · CA · contact PI
ADMINISTRATION$52,753
P30 · FY2015 · CA · contact PI
OHSU Knight Cancer Institute$1,540,000
P30 · FY2014 · CA · contact PI
Chronic Myelogenous Leukemia and BCR-ABL Substrates$300,984
R37 · FY2014 · CA · contact PI
Senior Leadership$230,336
P30 · FY2014 · CA · contact PI
Program Leadership$125,782
P30 · FY2014 · CA · contact PI
CLINICAL RESEARCH MANAGEMENT SHARED RESOURCE$125,772
P30 · FY2014 · CA · contact PI
OHSU Knight Cancer Institute$125,000
P30 · FY2014 · CA · contact PI
DEVELOPMENTAL FUNDS$120,473
P30 · FY2014 · CA · contact PI
DATA SAFETY MONITORING SYSTEMS$88,961
P30 · FY2014 · CA · contact PI
PROTOCOL REVIEW & MONITORING SYSTEM$79,617
P30 · FY2014 · CA · contact PI
PROGRAM PLANNING AND EVALUATION$77,659
P30 · FY2014 · CA · contact PI
OHSU Knight Cancer Institute$75,000
P30 · FY2014 · CA · contact PI
PROTEOMICS SHARED RESOURCE$70,560
P30 · FY2014 · CA · contact PI
BIOANALYTICAL/PHARACOKINETIC SHARED RESOURCE$70,560
P30 · FY2014 · CA · contact PI
HISTAPATHOLOGY & CANCER GENOTYPING SHARED RESOURCE$67,806
P30 · FY2014 · CA · contact PI
FLOW CYTOMETRY SHARED RESOURCE$63,201
P30 · FY2014 · CA · contact PI
PROTOCOL SPECIFIC RESEARCH SUPPORT$57,158
P30 · FY2014 · CA · contact PI
ADMINISTRATION$49,208
P30 · FY2014 · CA · contact PI
OHSU Knight Cancer Institute$1,061,540
P30 · FY2013 · CA · contact PI
Chronic Myelogenous Leukemia and BCR-ABL Substrates$291,676
R37 · FY2013 · CA · contact PI
Senior Leadership$160,219
P30 · FY2013 · CA · contact PI
OHSU Knight Cancer Institute$116,354
P30 · FY2013 · CA · contact PI
Senior Leadership$116,354
P30 · FY2013 · CA · contact PI
Program Leadership$86,681
P30 · FY2013 · CA · contact PI
CLINICAL RESEARCH MANAGEMENT SHARED RESOURCE$86,672
P30 · FY2013 · CA · contact PI
DEVELOPMENTAL FUNDS$84,218
P30 · FY2013 · CA · contact PI
Senior Leadership$75,000
P30 · FY2013 · CA · contact PI
OHSU Knight Cancer Institute$75,000
P30 · FY2013 · CA · contact PI
DATA SAFETY MONITORING SYSTEMS$61,306
P30 · FY2013 · CA · contact PI
PROTOCOL REVIEW & MONITORING SYSTEM$54,868
P30 · FY2013 · CA · contact PI
PROGRAM PLANNING AND EVALUATION$53,522
P30 · FY2013 · CA · contact PI
PROTEOMICS SHARED RESOURCE$48,631
P30 · FY2013 · CA · contact PI
BIOANALYTICAL/PHARACOKINETIC SHARED RESOURCE$48,627
P30 · FY2013 · CA · contact PI
HISTAPATHOLOGY & CANCER GENOTYPING SHARED RESOURCE$46,730
P30 · FY2013 · CA · contact PI
FLOW CYTOMETRY SHARED RESOURCE$43,559
P30 · FY2013 · CA · contact PI
PROTOCOL SPECIFIC RESEARCH SUPPORT$39,394
P30 · FY2013 · CA · contact PI
ADMINISTRATION$31,474
P30 · FY2013 · CA · contact PI
OHSU Knight Cancer Institute$1,135,337
P30 · FY2012 · CA · contact PI
Chronic Myelogenous Leukemia and BCR-ABL Substrates$310,293
R37 · FY2012 · CA · contact PI
Senior Leadership$174,905
P30 · FY2012 · CA · contact PI
OHSU Knight Cancer Institute$140,000
P30 · FY2012 · CA · contact PI
Program Leadership$92,449
P30 · FY2012 · CA · contact PI
CLINICAL RESEARCH MANAGEMENT SHARED RESOURCE$92,445
P30 · FY2012 · CA · contact PI
DEVELOPMENTAL FUNDS$91,124
P30 · FY2012 · CA · contact PI
OHSU Knight Cancer Institute$75,000
P30 · FY2012 · CA · contact PI
DATA SAFETY MONITORING SYSTEMS$65,418
P30 · FY2012 · CA · contact PI
PROTOCOL REVIEW & MONITORING SYSTEM$58,558
P30 · FY2012 · CA · contact PI
PROGRAM PLANNING AND EVALUATION$57,118
P30 · FY2012 · CA · contact PI
BIOANALYTICAL/PHARACOKINETIC SHARED RESOURCE$51,908
P30 · FY2012 · CA · contact PI
PROTEOMICS SHARED RESOURCE$51,908
P30 · FY2012 · CA · contact PI
HISTAPATHOLOGY & CANCER GENOTYPING SHARED RESOURCE$49,882
P30 · FY2012 · CA · contact PI
FLOW CYTOMETRY SHARED RESOURCE$46,503
P30 · FY2012 · CA · contact PI
PROTOCOL SPECIFIC RESEARCH SUPPORT$42,071
P30 · FY2012 · CA · contact PI
ADMINISTRATION$31,003
P30 · FY2012 · CA · contact PI
Senior Leadership$8,751
P30 · FY2012 · CA · contact PI
PROGRAM PLANNING AND EVALUATION$8,751
P30 · FY2012 · CA · contact PI
Program Leadership$8,751
P30 · FY2012 · CA · contact PI
BIOANALYTICAL/PHARACOKINETIC SHARED RESOURCE$8,750
P30 · FY2012 · CA · contact PI
CLINICAL RESEARCH MANAGEMENT SHARED RESOURCE$8,750
P30 · FY2012 · CA · contact PI
PROTEOMICS SHARED RESOURCE$8,750
P30 · FY2012 · CA · contact PI
FLOW CYTOMETRY SHARED RESOURCE$8,750
P30 · FY2012 · CA · contact PI
HISTAPATHOLOGY & CANCER GENOTYPING SHARED RESOURCE$8,750
P30 · FY2012 · CA · contact PI
ADMINISTRATION$8,750
P30 · FY2012 · CA · contact PI
DEVELOPMENTAL FUNDS$8,750
P30 · FY2012 · CA · contact PI
PROTOCOL SPECIFIC RESEARCH SUPPORT$8,749
P30 · FY2012 · CA · contact PI
DATA SAFETY MONITORING SYSTEMS$8,749
P30 · FY2012 · CA · contact PI
PROTOCOL REVIEW & MONITORING SYSTEM$8,749
P30 · FY2012 · CA · contact PI
Senior Leadership$4,689
P30 · FY2012 · CA · contact PI
Program Leadership$4,689
P30 · FY2012 · CA · contact PI
PROGRAM PLANNING AND EVALUATION$4,688
P30 · FY2012 · CA · contact PI
DEVELOPMENTAL FUNDS$4,688
P30 · FY2012 · CA · contact PI
ADMINISTRATION$4,688
P30 · FY2012 · CA · contact PI
HISTAPATHOLOGY & CANCER GENOTYPING SHARED RESOURCE$4,688
P30 · FY2012 · CA · contact PI
DATA SAFETY MONITORING SYSTEMS$4,687
P30 · FY2012 · CA · contact PI
BIOANALYTICAL/PHARACOKINETIC SHARED RESOURCE$4,687
P30 · FY2012 · CA · contact PI
FLOW CYTOMETRY SHARED RESOURCE$4,687
P30 · FY2012 · CA · contact PI
PROTEOMICS SHARED RESOURCE$4,687
P30 · FY2012 · CA · contact PI
CLINICAL RESEARCH MANAGEMENT SHARED RESOURCE$4,687
P30 · FY2012 · CA · contact PI
PROTOCOL REVIEW & MONITORING SYSTEM$4,687
P30 · FY2012 · CA · contact PI
PROTOCOL SPECIFIC RESEARCH SUPPORT$4,687
P30 · FY2012 · CA · contact PI
OHSU Knight Cancer Institute$1,135,337
P30 · FY2011 · CA · contact PI
Chronic Myelogenous Leukemia and BCR-ABL Substrates$294,776
R37 · FY2011 · CA · contact PI
DEVELOPMENTAL FUNDS$148,888
P30 · FY2011 · CA · contact PI
OHSU Knight Cancer Institute$139,999
P30 · FY2011 · CA · contact PI
Program Leadership$109,056
P30 · FY2011 · CA · contact PI
CLINICAL RESEARCH MANAGEMENT SHARED RESOURCE$109,056
P30 · FY2011 · CA · contact PI
Senior Leadership$105,869
P30 · FY2011 · CA · contact PI
ADMINISTRATION$98,026
P30 · FY2011 · CA · contact PI
DATA SAFETY MONITORING SYSTEMS$77,192
P30 · FY2011 · CA · contact PI
OHSU Knight Cancer Institute$74,993
P30 · FY2011 · CA · contact PI
PROGRAM PLANNING AND EVALUATION$72,600
P30 · FY2011 · CA · contact PI
PROTOCOL REVIEW & MONITORING SYSTEM$69,101
P30 · FY2011 · CA · contact PI
HISTAPATHOLOGY & CANCER GENOTYPING SHARED RESOURCE$62,080
P30 · FY2011 · CA · contact PI
PROTEOMICS SHARED RESOURCE$61,258
P30 · FY2011 · CA · contact PI
BIOANALYTICAL/PHARACOKINETIC SHARED RESOURCE$61,257
P30 · FY2011 · CA · contact PI
FLOW CYTOMETRY SHARED RESOURCE$54,884
P30 · FY2011 · CA · contact PI
PROTOCOL SPECIFIC RESEARCH SUPPORT$49,661
P30 · FY2011 · CA · contact PI
OHSU Knight Cancer Institute$1,145,093
P30 · FY2010 · CA · contact PI
Accelerating target identification and validation in leukemia: Integrating siRNA-$499,955
RC1 · FY2010 · CA · contact PI